Genome-wide insights into the shared genetic landscape between metabolic

1

# dysfunction-associated fatty liver disease and cardiovascular diseases 2 Jun Qiao<sup>1,2,9</sup>, Miaoran Chen<sup>3,9</sup>, Minjing Chang<sup>4,9</sup>, Wenjia Xie<sup>3</sup>, Wengi Ma<sup>3</sup>, Tongtong 3 Yang<sup>3</sup>, Qianru Zhao<sup>3</sup>, Kaixin Yao<sup>3</sup>, Xichen Yang<sup>3</sup>, Quan Yun<sup>3</sup>, Jing Xiao<sup>2,5</sup>, Xu He<sup>2,5</sup>, 4 Wen Su<sup>6\*</sup>, Tao Xu<sup>7,8\*</sup>, Yuliang Feng<sup>1,10\*</sup>, Meixiao Zhan<sup>2,5\*</sup> 5 <sup>1</sup> Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong 6 7 Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern 8 University of Science and Technology, Shenzhen, China. <sup>2</sup> Guangzhou First Pepople's Hospital, the Second Affiliated Hospital, School of 9 Medicine, South China University of Technology, Guangzhou, China. 10 <sup>3</sup> Department of Nephrology, Shanxi Kidney Disease Institute, Second Hospital of 11 12 Shanxi Medical University, Taiyuan, China. <sup>4</sup> School of Public Health and Emergency Management, School of Medicine, 13 Southern University of Science and Technology, Shenzhen, China. 14 <sup>5</sup> Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and 15 Treatment, Zhuhai People's Hospital, Zhuhai Clinical Medical College of Jinan 16 University, Zhuhai, China. 17 <sup>6</sup> Department of Pathophysiology, Shenzhen University Health Science Center, 18 Shenzhen University, Shenzhen, China. 19 <sup>7</sup> Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui 20 21 Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, 22 China.

- <sup>8</sup> Institute for Liver Diseases of Anhui Medical University, Hefei, China.
- <sup>9</sup>These authors contributed equally to this work.
- <sup>10</sup>Lead Contact.
- 26
- 27 \*Corresponding author:
- 28 Meixiao Zhan MD, PhD
- 29 Professor
- 30 Guangzhou First Pepople's Hospital, the Second Affiliated Hospital, School of
- 31 Medicine, South China University of Technology, Guangzhou, 510006, China.
- 32 Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and
- 33 Treatment, Zhuhai People's Hospital, Zhuhai Clinical Medical College of Jinan
- 34 University, Zhuhai, 510009, China.
- 35 Tel:+86-(020)81048319
- 36 Email: <u>zhanmeixiao@ext.jnu.edu.cn</u>
- 37
- 38 Yuliang Feng MD, PhD
- 39 Associate Professor
- 40 Department of Pharmacology, School of Medicine; Southern University of Science
- 41 and Technology, Shenzhen, Guangdong, 518055, China.
- 42 Tel:+86 (755)-88012564
- 43 Email: <u>fengyl@sustech.edu.cn</u>
- 44

- 45 Tao Xu PhD
- 46 Professor
- 47 Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui
- 48 Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei,
- 49 230032, China.
- 50 Institute for Liver Diseases of Anhui Medical University, Hefei, 230032, China.
- 51 Tel: +86 (0551)-65172131
- 52 Email: <u>xutao@ahmu.edu.cn</u>
- 53
- 54 Wen Su MD, PhD
- 55 Associate Professor
- 56 Department of Pathophysiology, Shenzhen University Health Science Center,
- 57 Shenzhen University, Shenzhen, 518071, China.
- 58 Tel:+86 18188610625
- 59 Email: <u>suwen@szu.edu.cn</u>
- 60

- 61 Keywords: Metabolic dysfunction-Associated fatty liver disease, Cardiovascular
- 62 diseases, genome-wide association studies, Shared genetic architectures, Genetic
- 63 pleiotropy.
- 64
- 65 Abstract: 275 words
- 66 Electronic word count manuscript: 4,568 words
- 67 Main figures and tables: 4 main figures, 1 main tables
- 68 Supplementary material: 2
- 69

## 70 Conflict of interest statement

- 71 All authors declare no competing interests.
- 72

#### 73 **Financial support statement**

74 This study was supported by the Natural Science Foundation of China Excellent 75 Young Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and 76 Applied Basic Research Foundation for Distinguished Young Scholars (Grant no. 2024B1515020047), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research 77 General Projects of Shenzhen Science and Technology Innovation Commission (Grant 78 79 no. JCYJ20230807093514029) (To Y.F.), Shenzhen University 2035 Program for Excellent Research 8690200000314, the Shenzhen Science and Technology Fund for 80 81 Distinguished Young Scholars (RCYX20231211090127031) (to W. S.), National 82 Natural Science Foundation of China (Grant no. 82230067, 82272103), the

83	Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and
84	Treatment (Grant no. 2021B1212040004), and the Natural Science Foundation of
85	Guangdong Province of China (Grant no. 2022B1515020010) (To M.Z.), Shenzhen
86	Science and Technology Program (Grant No. GJHZ20240218111401002 to J.B.), and
87	Center for Computational Science and Engineering at Southern University of Science
88	and Technology. The funder had no role in the design, implementation, analysis,
89	interpretation of the data, approval of the manuscript, and decision to submit the
90	manuscript for publication.

91

## 92 Author contributions

J.Q., M.C., M.C., Y.F., and M.Z. as conceptualization and supervised this project and
wrote the manuscript. W.X., W.M., T.Y., Q.Z., and K.Y. performed the main analyses
and wrote the manuscript. X.Y, Q.Y., J.X., and X.H. performed the statistical analysis
and assisted with interpreting the results. W.S., T.X., Y.F., and M.Z. provided expertise
in cardiovascular biology and GWAS summary statistics. All authors provided
intellectual content and approved the final version of the manuscript.

## 99 Abstract

Background& Aims : Multiple epidemiological studies have suggested an association
between Metabolic dysfunction-associated fatty liver disease (MAFLD) and
cardiovascular diseases (CVDs). However, the genetic components that are shared
between the two remain unclear.

104 Methods: This genome-wide pleiotropic association study integrated comprehensive 105 genome-wide association studies (GWAS) summary data from publicly available 106 sources within European populations. It employed a range of genetic approaches to 107 analyze the shared genetic architectures between MAFLD and six CVDs: atrial fibrillation (AF), coronary artery disease (CAD), venous thromboembolism (VTE), 108 109 heart failure (HF), peripheral artery disease (PAD), and stroke. Initially, we examined 110 the genetic correlation and overlap between these conditions. Subsequently, 111 Mendelian Randomization (MR) analysis was conducted to investigate potential 112 causal relationships. Finally, we explored horizontal pleiotropy at the levels of single 113 nucleotide polymorphisms (SNPs), genes, and biological pathways to further 114 elucidate the shared genetic mechanisms underlying.

**Results:** We observed significant genetic associations between MAFLD and four CVDs, including CAD, HF, PAD, and VTE. However, we noted extensive genetic overlap in all but MAFLD-AF. MR analysis established causal relationships from MAFLD to both AF and PAD. Regarding horizontal pleiotropy, 49 pleiotropic loci were identified at the SNP level with functional annotations, 13 demonstrating strong evidence of colocalization. At the gene level, 14 unique pleiotropic genes were found,

121	with SAMM50 (located at 22q13.31) being particularly notable. Further pathway
122	enrichment analysis indicated that these genes significantly contribute to the pathway
123	of establishment of protein localization to membrane, highlighting their pivotal role in
124	the pathophysiology of both MAFLD and CVD.
125	Conclusions : In all, our research proved the shared genetic architectures and
126	mechanisms between MAFLD and CVD and elucidated their shared genetic etiology
127	and biological mechanisms.


128

#### 129 **Impact and implications**

Metabolic dysfunction-associated fatty liver disease (MAFLD) has reached a 130 131 prevalence of 25-30% worldwide and has emerged as a global leading cause of 132 liver-related morbidity and mortality. Studies have shown that people with MAFLD 133 have a higher risk of cardiovascular disease (CVD) than the general population and 134 there is currently no effective drug to treat the comorbidity of the two, which imposes 135 a burden on the socioeconomic situation and the adverse effects are still rising. 136 Therefore, it is critical to understand how MAFLD affects CVD. Our study provides 137 unique insights into the mechanisms of comorbidity between MAFLD and CVD. The increasing number of complications has prompted us to explore new treatment options, 138 139 so our study has important clinical significance.

140

#### 141 **Graphical abstract**



## 144 Highlights:

- 145 The first comprehensive and systematic study to explore the common genetic
- components between MAFLD and CVD.
- MAFLD and CVDs share genetic architectures and mechanisms.
- Genetically predicted MAFLD increases the risk of AF and PAD.
- The effects of *SAMM50* (located at 22q13.31) on lipid metabolism support the
- 150 comorbidity of MAFLD and CVDs.
- 151 The localization of lipid droplet related contact site proteins to the membrane
- 152 plays a key role in the comorbidity of MAFLD and CVD.

## 153 Introduction

154 Non-alcoholic fatty liver disease (NAFLD) encompasses a range of liver disorders, 155 from simple steatosis to non-alcoholic steatohepatitis, fibrosis, and cirrhosis, typically 156 arising without significant alcohol consumption. According to a recent consensus 157 statement by an international panel of experts, Metabolic dysfunction-Associated fatty 158 liver disease (MAFLD) has been proposed as a more appropriate and comprehensive 159 term to replace NAFLD, better reflecting its association with known metabolic dysfunctions<sup>1,2</sup>. MAFLD has emerged as a global leading cause of liver-related 160 morbidity and mortality<sup>3</sup>. While liver-related complications significantly elevate 161 mortality rates, cardiovascular diseases (CVDs) remain the primary cause of death in 162 patients with MAFLD<sup>4</sup>. Clinically, individuals with MAFLD often exhibit elevated 163 164 triglyceride levels and an increased concentration of residual lipoprotein particles, thereby elevating their risk for CVDs<sup>5</sup>. Lipoproteins containing apolipoprotein C3 165 166 (ApoC3) have been shown to activate the IL(interleukin)-1 to IL-6 to CRP 167 (C-Reactive Protein) inflammatory pathway, which is implicated in the development 168 of coronary artery disease (CAD), venous thromboembolism (VTE), Stroke, and vascular inflammation<sup>6</sup>. A meta-analysis of 16 observational studies, encompassing 169 170 34,043 patients over a median follow-up of 6.9 years, reported a 64% increased risk 171 of fatal and/or non-fatal CVD events in patients with MAFLD compared to those without<sup>7</sup>. The strong epidemiological evidence underscores the association between 172 173 MAFLD and an escalated risk of CVDs, which might suggest increased genetic 174 liability to CVD in subgroups of patients with MAFLD.

176	Enhanced comprehension of the shared genetic foundations between MAFLD and
177	various CVDs could offer valuable insights into these conditions. Recent large-scale
178	genome-wide association studies (GWAS) have uncovered numerous risk loci linked
179	to both MAFLD and CVDs, identifying several shared risk loci, notably at 19p13.11
180	(TM6SF2) <sup>8</sup> and 22q13.31 (PNPLA3) <sup>9</sup> . Increasing evidence suggests genetic overlap
181	between MAFLD and CVDs. For instance, recent data suggested weak to moderate
182	positive genetic correlations between MAFLD and CAD, heart failure (HF), and
183	Hypertension, a major risk factor for CVDs <sup>10</sup> . Genetic correlation provides a
184	summary measure of the correlation across all single-nucleotide polymorphism (SNP)
185	effect sizes. However, it cannot differentiate between genetic overlap with a
186	combination of concordant and discordant effects and a complete absence of genetic
187	overlap, frequently resulting in an estimate close to 0 in both scenarios <sup>11</sup> . While
188	genetic correlation can provide evidence for overall genomic similarity between traits,
189	it does not provide information for considering biological plausibility or inferring
190	potential causal relationships <sup>12</sup> . Previous Mendelian randomization(MR) analyses
191	investigating the link between MAFLD and CVDs have shown that the causal
192	relationship was not consistently robust due to possible bias by the presence of
193	horizontal pleiotropy or sample overlap <sup>13-15</sup> . Despite these insights, a significant
194	portion of the genetic underpinnings of MAFLD and CVDs remain elusive. Moreover,
195	individual loci associated with both conditions have not been systematically analyzed,
196	an examination of which could clarify the impact of different risk loci on the

197 comorbidities of MAFLD and CVDs, as well as identify biological pathways offering198 therapeutic promise.

199

200 This study aims to uncover their genetic overlap beyond the genetic correlation 201 between MAFLD and six major CVDs-atrial fibrillation (AF), CAD, VTE, HF, 202 peripheral artery disease (PAD), and Stroke-by leveraging unprecedentedly large 203 GWAS summary data from European ancestry. We applied the genetic analysis 204 incorporating pleiotropy and annotation (GPA), which estimates the total number of 205 unique and shared genetic variants between pairs of traits. The relevance of mixed 206 effects has been further emphasized by Local Analysis of [co]Variant Annotation 207 (LAVA), which calculates local genetic correlations across the genome, even in the 208 presence of minimal  $r_g$ . Given that GPA and LAVA quantify total genetic overlap but 209 cannot pinpoint shared genomic loci, we subsequently utilized the Pleiotropic 210 Analysis under a Composite Null Hypothesis (PLACO) method to discover loci 211 jointly associated with MAFLD and each CVD beyond genome-wide significance, a 212 critical step for gaining biological insights. Additionally, we also utilize Latent 213 Heritable Confounder Mendelian randomization (LHC-MR) analyses to explore 214 potential causal relationships between MAFLD and CVDs, considering sample 215 overlap, bidirectional causal associations, and unobserved heritable confounders. 216 Together, these methods augment the insights gained from genetic correlation 217 analyses, shedding light on the distinct and common genetic frameworks 218 underpinning MAFLD and CVDs, with implications for how we conceptualize

219 genetic risk for the comorbidity between MAFLD and CVDs.

220

#### 221 Materials and methods

#### 222 Data sources and quality control

Genetic associations with MAFLD were derived from the largest genome-wide 223 224 meta-analysis to date, involving 8,434 cases and 770,180 controls from four European 225 cohorts: the Electronic Medical Records and Genomics (eMERGE) Network, the UK 226 Biobank (UKB), the Estonian Biobank (EstBB), and the FinnGen Consortium, of 227 which the diagnosis was determined based on the electronic health records of all participants<sup>16</sup>. To ensure that the sample size is large enough to produce reliable 228 229 results, we use GWAS summary data from studies with sample sizes greater than 230 50,000. Accordingly, our study encompassed six major CVDs, including AF, CAD, 231 VTE, HF, PAD, and Stroke. Specifically, GWAS summary statistics for AF were 232 retrieved from a recent meta-analysis of six cohorts, including the Health Study 233 Nord-Trøndelag (HUNT), deCODE, Michigan Genome Initiative (MGI), DiscovEHR, 234 UKB, and AFGen consortium, comprising 60,620 cases and 970,216 controls of European ancestry<sup>17</sup>. GWAS summary statistics for CAD were extracted from a 235 236 genome-wide meta-analysis by the CARDIoGRAMplusC4D and UKB consortium, including 181,522 cases and 984,168 controls of European ancestry<sup>18</sup>. GWAS 237 238 summary statistics for VTE were collected from the largest meta-analysis of seven cohorts to date, including 81,190 cases and 1,419,671 controls of European ancestry<sup>19</sup>. 239 240 GWAS summary data for HF were derived from the Heart Failure Molecular

241	Epidemiology for Therapeutic Targets (HERMES) consortium, entailing 47,309 cases
242	and 930,014 controls <sup>20</sup> . GWAS summary data for PAD came from the largest
243	meta-analysis conducted on data from 11 independent cohorts, totaling 12,086 cases
244	and 499,548 controls <sup>21</sup> . GWAS summary data for Stroke were obtained from the
245	GIGASTROKE consortium, which included 73,652 cases and 1,234,808 controls <sup>22</sup> .
246	Detailed information about these GWAS summary data and their original publication
247	sources is available in Supplementary Table 1.

248

Quality control was carried out strictly for GWAS summary data per the following steps before further analysis:(i) alignment with the hg19 genome assembly, and the 1000 Genomes Project v3 Europeans was used as the reference<sup>23</sup>; (ii) only including autosomal SNPs; (iii) SNPs with duplicate entries or missing rsIDs were eliminated; (iv) SNPs with a minor allele frequency (MAF) value of 0.01 or less were excluded. To ensure robust results, we normalized the GWAS summary data for all phenotypic SNPs, yielding 6,479,654 common SNPs across all diseases.

256

#### 257 Assessing the genetic correlates of MAFLD and CVDs

We employed cross-trait linkage disequilibrium score regression (LDSC) analyses to assess the genetic correlation ( $r_g$ ) between MAFLD and six major CVDs<sup>24</sup>. LDSC, an effective method for evaluating genetic correlations across the genome, utilizes the linkage disequilibrium (LD) structure to estimate individual SNP effect sizes from GWAS summary statistics<sup>25</sup>. The method involves regression of these GWAS summary statistics against LD scores derived from the European 1000 Genomes Project, minimizing biases related to polygenicity, sample overlap, and population

stratification<sup>24</sup>. Due to its complexity, the major histocompatibility complex (MHC) 265 266 region was excluded from our analysis. First, univariate LDSC was conducted to determine the SNP-based heritability  $(h^2_{SNP})$  for MAFLD and each CVD. 267 Subsequently, bivariate LDSC estimated the  $r_g$  between MAFLD and CVDs by 268 performing a weighted linear regression on the product of Z-scores for MAFLD and 269 CVDs against the LD scores for all available genetic variants. This approach provides 270 an unbiased estimate of  $r_g$  and reliably measures genetic correlations even in 271 overlapping samples between GWAS datasets. Genetic correlations rang from -1 to +1, 272 273 with values closer to the extremes indicating stronger influences, and negative values 274 suggest opposite-direction effects, while positive values indicate the same direction. *P*-values below a Bonferroni-corrected significance threshold ( $P = 0.05 / 6 = 8.3 \times 10^{-3}$ ) 275 276 were considered statistically significant.

277

278 To identify tissues closely associated with genetic susceptibility SNPs for MAFLD and CVDs, we used LDSC applied to specifically expressed genes (LDSC-SEG)<sup>26</sup>. 279 280 This method combines aggregate GWAS summary statistics with tissue-specific gene expression data for targeted tissue enrichment analysis<sup>26</sup>. Our analysis incorporated 281 282 various gene sets, including multi-tissue gene expression data from the GTEx project (v8) and chromatin information from the Roadmap Epigenomics and ENCODE 283 initiatives<sup>26,27</sup>. Using the baseline model and comprehensive gene sets, we prioritized 284 genes from GTEx based on computed t-statistics, focusing on the top 10% of 285 specifically expressed candidate genes that exhibited the highest t-statistics. The 286 287 P-value from the regression coefficient's z-score was used to determine the significance coefficient, and a false discovery rate (FDR) of less than 0.05 was 288 289 applied to assess the significance of enriched SNPs in specific tissues.

290

### 291 Estimating genetic overlap between MAFLD and CVDs

To address the "missing heritability" issue in complex traits, the Genetic Analysis incorporating Pleiotropy and Annotation (GPA) was specifically developed. This tool

294 was specifically designed to overcome the limitations posed by the small proportion of genetic variants identified through standard approaches that account for only a 295 minimal part of the expected genetic contribution<sup>28</sup>. GPA achieves this by integrating 296 diverse genomic data and annotation information, thereby enhancing the prioritization 297 298 of GWAS results and providing a more comprehensive estimation of genetic overlap. Notably, in the absence of annotation data, GPA can infer genetic overlap using 299 p-value interactions of the corresponding phenotypes<sup>28</sup>. GPA is based on key 300 assumptions regarding p-value distributions: p-values from null SNPs are expected to 301 302 adhere to a uniform distribution, reflecting no association, while p-values from 303 non-null SNPs are presumed to follow a beta distribution, indicating potential 304 associations. Within this framework, GPA categorizes SNPs into four groups based on 305 their p-value characteristics:  $\pi 00$  suggests no association with either trait;  $\pi 01$  denotes 306 an association exclusively with the first trait;  $\pi 10$  signifies an association solely with 307 the second trait; and  $\pi 11$  represents an association with both traits. This classification 308 can estimate  $\pi 11 / (\pi 10 + \pi 11 + \pi 11)$ , an important ratio indicator that represents the 309 proportion of SNPS shared by two traits, suggesting the extent to which a common biological pathway may be shared between the two traits<sup>28</sup>. Subsequently, the 310 likelihood ratio test (LRT) was used to assess the statistical significance of the 311 observed genetic overlap<sup>28</sup>. Given the complex interrelations among SNPs, GPA 312 estimates are susceptible to biases from LD. We used PLINK1.9 for LD pruning to 313 address this, drawing on data from the 1000 Genomes Project Phase 3<sup>23</sup> for European 314 ancestry. We also applied a Bonferroni-corrected significance threshold for multiple 315 comparisons, set at P = 0.05 / number of trait pairs = 0.05 /  $6 = 8.3 \times 10^{-3}$ . 316

317

## 318 Calculating local genetic correlations between MAFLD and CVDs

LAVA facilitates the assessment of local genetic correlations by partitioning the genome into smaller regions, which enables detailed insights into the influence of genetic variants on various traits at a regional level, rather than across the entire genome<sup>29</sup>. LAVA analyses genetic correlations within different genomic segments,

using the regions delineated by Werme et al. as autosomal LD blocks<sup>29</sup>, characterized 323 324 by minimal connectivity between blocks. The genome was partitioned into 2,495 325 semi-independent regions, each approximately 1 Mb, using genotype data from the 326 1000 Genomes Project Phase 3 European ancestry as the LD reference panel and 327 MHC region (chr 6: 25-35 Mb) was excluded. In conducting the genetic association 328 study, we first performed a preliminary univariate analysis using LAVA to estimate the 329 local heritability of MAFLD and CVDs. With this step, we could identify regions that 330 showed significant signals in the local genetic analysis. We then performed bivariate 331 LAVA analyses of these regions to explore regional genetic associations between 332 MAFLD and CVDs. To ensure the statistical significance of the results, the FDR 333 method was employed to calculate the adjusted p-value. FDR less than 0.05 was 334 considered the genetic correlation of these regions to be statistically significant.

335

#### **Evaluate the causal relationship between MAFLD and CVDs**

337 The genome-wide and local genetic correlations provide insights into the shared 338 genetic basis between trait pairs, but these correlations do not imply causality in either 339 direction. To overcome these limitations, linkage disequilibrium heterogeneity causal 340 Mendelian randomization (LHC-MR) provides a more refined approach to assess bidirectional causality while minimizing confounding effects<sup>30</sup>. This method extends 341 342 traditional MR by addressing limitations of the standard two-sample MR approach, such as potential sample overlap, under-utilization of genome-wide markers, and the 343 344 need to understand exposure-outcome relationships. LHC-MR assesses bidirectional 345 causality by categorizing associations between exposure and outcome into four 346 categories: (i) causal effect of exposure on outcome, (ii) causal effect of outcome on 347 exposure, (iii) effect of confounders whose exposure affects the outcome process

348 (vertical pleiotropy), and (iv) effect of confounders whose exposure affects the outcome independently (horizontal pleiotropy<sup>30</sup>). Unlike traditional MR, LHC-MR 349 350 utilizes all genome-wide genetic variation rather than only genome-wide significant variation<sup>30</sup>. To ensure the stability of the results, the Bonferroni correction 351 significance threshold was set at  $4.17 \times 10^{-3}$  (P = 0.05/number of trait pairs/number of 352 tests). When  $P_{axy} < 4.17 \times 10^{-3}$  and  $P_{ayx} > 0.05$ , it suggests a one-way causal 353 relationship from MAFLD to CVD; conversely, when  $P_{ayx} < 4.17 \times 10^{-3}$  and  $P_{axy} > 0.05$ , 354 355 it implies a one-way causal relationship from CVD to MAFLD. However, if both  $P_{axy}$ and  $P_{ayx}$ , exceeding the significance threshold, it indicates bidirectional causality 356 357 between MAFLD and CVD. We used traditional two-sample MR techniques for 358 sensitivity analysis, including Inverse Variance Weighting (IVW), MR Egger, 359 Weighted Median, Simple Mode, and Weighted Mode. P-values below the 0.05 360 threshold were considered statistically significant.

361

#### 362 Identification of pleiotropic loci between MAFLD and CVDs

To unravel the shared genetic mechanisms between MAFLD and six major CVDs, our study employs the PLACO, extending pleiotropic analysis to the SNP level<sup>31</sup>. PLACO utilizes the summary statistic from GWAS to calculate the test statistic for the product of the Z-statistics for each SNP in the two trait analyses. This calculation is based on the assumption of a mixed distribution, which allows for the assessment of SNP associations across traits. Using this assumption, PLACO can rigorously analyze individual SNPs by pairwise Z-statistics, categorizing the null hypothesis of

370	pleiotropy into three distinct and mutually exclusive scenarios: (i) H00, indicating no
371	association of the SNP with either trait; (ii) H10, signifying an association with the
372	first trait but not the second; and (iii) H01, representing an association with the second
373	trait but not the first. The rejection of the composite null hypothesis, which
374	encompasses all three scenarios, indicates horizontal pleiotropy, suggesting that the
375	SNP influences both traits through identical mechanisms. We applied a stringent
376	significance threshold of $5 \times 10^{-8}$ to identify SNPs exhibiting statistically significant
377	pleiotropy.

378

### 379 Functional annotation based on pleiotropic loci

380 To identify and conduct independent genomic loci between MAFLD and six major CVDs, we utilized the Functional Mapping and Annotation (FUMA) platform<sup>32</sup>. 381 382 FUMA, an online tool designed to enhance the interpretability of GWAS findings, performs functional annotation of pleiotropic SNPs revealed by PLACO analysis. 383 384 Lead SNPs are merged to delineate distinct genomic loci in LD blocks within 500 kb of lead SNPs by FUMA, utilizing default parameters and LD data from the 1000 385 Genomes Project Phase 3 European cohort. Lead SNP was further selected by  $r^2 < 0.1$ 386 for minimal LD in independent significant SNPs (genome-wide significance P < P387  $5 \times 10^{-8}$  and  $r^2 < 0.6$ ), indicating higher independence from adjacent genetic variations. 388 389 Despite these regions potentially containing several lead SNPs, the Top Lead SNP is 390 identified with the lowest P-value within a given region. Locus was deemed novel to 391 MAFLD and CVD if they did not coincide with the loci previously reported in the

392 original GWAS.

393

394	Functional annotations for Top Lead SNPs, provided by FUMA, include Combined
395	Annotation-Dependent Depletion (CADD <sup>33</sup> ) scores, regulatory function probability
396	scores via RegulomeDB (RDB <sup>34</sup> ), and potential effects on gene function as annotated
397	by ANNOVAR <sup>35</sup> . CADD scores, which assess the harmful impact of SNPs, are
398	utilized with a threshold: a score greater than 12.37 is considered likely to be harmful,
399	reflecting the SNP's potential to affect biological functions adversely. RDB scores,
400	ranging from 1 to 7, indicate the likelihood of an SNP being located in a regulatory
401	function area, with lower scores denoting higher functional significance. Lead SNPs
402	were annotated using ANNOVAR to evaluate their proximity to genes and potential
403	impacts on gene functions, thus providing insights into how these variants might
404	influence genetic pathways or disease mechanisms. For the identification of putative
405	causal genes, SNPs were mapped using two approaches: positional mapping within a
406	10-kb window around the SNP and eQTL mapping.

407

## 408 Colocalization analysis

After annotating pleiotropic loci using FUMA, we analyzed colocalization with the "COLOC" R package to identify potential shared causal variants across trait pairs within each locus. COLOC analysis employs Bayes factors to evaluate the likelihood of shared causal variation between two sets of trait-associated loci, calculating posterior probabilities (PP) for five mutually exclusive hypotheses at each locus: (i)

414	no SNP is associated with either trait (H0); (ii) a causal SNP is associated only with
415	the first trait (H1); (iii) a causal SNP is associated only with the second trait (H2); (iv)
416	each trait is influenced by independent, distinct causal SNPs (H3); and (v) a single
417	SNP acts as a causal variant for both traits (H4). Our analysis primarily focuses on
418	hypothesis H4, which posits a shared causal variant for both traits. Strong evidence of
419	colocalization at a genomic locus is indicated if the posterior probability for shared
420	causal variants (PPH4) exceeds 0.70. The SNP with the highest PPH4 within these
421	loci is identified as the candidate causal variant.

422

### 423 Gene-level annotation analysis

424 To pinpoint genes that exhibit pleiotropic effects within genomic loci, a Multi-marker 425 Analysis of GenoMic Annotation (MAGMA) was performed based on the results of PLACO and individual GWAS<sup>36</sup>. MAGMA, a tool rooted in multivariable regression 426 427 models, computes the significance of gene-trait associations by incorporating 428 principal component analysis. It then employs the F-test to ascertain p-values for each 429 gene, considering factors such as gene size, SNP count per gene, and LD among the 430 markers. Consistency in gene-based testing was ensured by defining gene boundaries, which encompassed regions extending  $\pm 10$  kb from the termini of each gene. We 431 432 obtained MAGMA gene IDs and location data for 17,636 protein-coding genes, 433 aligning SNP locations with Human Gene Build 37 (GRCh37/hg19). The MHC 434 region (chr6: 25-35 Mb) was excluded from MAGMA's gene-based analysis. 435 Significant gene associations were identified using a stringent Bonferroni-corrected

436 threshold set at  $P = 4.73 \times 10^{-7}$  (0.05 / 17,636 / 6), accounting for the number of 437 protein-coding genes and trait pairs analyzed.

438

439 Recognizing that MAGMA links SNPs to genes based primarily on physical proximity, we extended our analysis to include the eQTL-informed MAGMA 440 (e-MAGMA)<sup>37</sup>. The e-MAGMA utilizes tissue-specific eQTL data to assign risk 441 442 variants to presumptive genes, thereby converting genome-wide association summary 443 statistics into gene-specific metrics. This method leverages tissue-specific eQTL data 444 from the GTEx project to account for long-range regulatory effects, enhancing the 445 interpretation of GWAS association signals. MHC region (chr6: 25-35 Mb) was 446 excluded in e-MAGMA analysis results as well as MAGMA to avoid confounding 447 due to complex LD patterns. Our study utilizes the GTEx v8 comprehensive database 448 containing eQTL data from 47 different tissues, based on PLACO results, to delve 449 into gene-disease associations at a fine-grained tissue level, and to gain a more 450 detailed understanding of the tissue-specific genetic architecture behind the relevant 451 diseases. To minimize confounding factors associated with broad tissue analyses, we refined our approach by selecting a subset of tissues based on insights from 452 453 LDSC-SEG results and previous research. Specifically, our focused analysis included 454 ten tissues: two types of adipose tissue (subcutaneous and visceral omental fat), three 455 arterial tissues (aorta, coronary, and tibial arteries), two cardiac tissues (left ventricle 456 and atrial appendage), as well as liver, EBV-transformed lymphocytes, and whole 457 blood. Using the 1000 Genomes Project v3 European samples as the LD reference, we

458 calculated tissue-specific p-values for each gene across the selected tissues. We 459 applied a Bonferroni correction to determine the significance of these p-values, 460 accounting for the number of tissue-specific protein-coding genes and trait pairs 461 examined. For instance, the significance threshold for adipose subcutaneous tissue 462 was set at  $P = 0.05 / 7,560 / 6 = 1.10 \times 10^{-6}$ .

463

464 To further explore tissue-specific gene-trait associations for MAFLD and CVDs, we 465 conducted a transcriptome-wide association study (TWAS) using single-trait GWAS results<sup>38</sup>. Employing the FUSION framework, TWAS integrates GWAS summary 466 statistics with eQTL data from the GTEx v8 dataset to assess how variations in gene 467 468 expression across specific tissues influence phenotypes. We used pre-computed gene 469 expression weight references from the tissues analyzed in our e-MAGMA study. LD 470 pruning was performed during the third phase of the 1000 Genomes Project using the LD structures of the European subpopulation. Significance thresholds were adjusted 471 472 using tissue-specific Bonferroni corrections to control for multiple tests.

473

#### 474 **Pathway level analyses**

We performed functional enrichment analysis on the overlapped gene lists significantly identified by MAGMA and e-MAGMA analyses using the ToppGene functional annotation tool (ToppFun)<sup>39</sup>. ToppGene Suite is a comprehensive portal for gene list enrichment analysis and candidate gene prioritization. The ToppFun application provides a variety of annotation data types, including transcriptome,

480	proteome, regulatory elements (such as transcription factor binding sites (TFBS) and
481	microRNA), ontologies (such as GO and Pathway), phenotypes (including human
482	diseases and mouse phenotypes), pharmacometrics (drug-gene associations), and
483	literature co-citations. Additionally, ToppFun prioritizes candidate genes based on
484	their functional similarity to ensure rigorous and thorough analysis. Significant GO
485	terms were identified with an FDR threshold of 0.05.

486

487 **Results** 

#### 488 SNP-based heritability and genetic correlations between MAFLD and CVDs

489 After harmonizing and filtering SNPs common across GWAS summary statistics, LDSC was utilized to estimate the  $h_{SNP}^2$  and the genome-wide genetic correlations  $(r_g)$ 490 between MAFLD and CVDs. Univariate LDSC analysis indicated that the  $h_{SNP}^2$  of 491 MAFLD was 0.002 (SE = 0.001). In comparison, the  $h_{SNP}^2$  of CVDs ranged from 492 0.008 to 0.032, with CAD exhibiting the highest heritability ( $h_{SNP}^2 = 0.032$ , SE = 493  $1.90 \times 10^{-3}$ ) and HF the lowest ( $h_{SNP}^2 = 0.008$ , SE =  $3.01 \times 10^{-3}$ ). Notably, the 494 495 heritability of MAFLD was lower than that of any individual CVD. Bivariate LDSC revealed that all trait pairs exhibited positive genetic correlations under a relaxed 496 significance threshold (P < 0.05). However, four trait pairs maintained statistical 497 significance after applying a Bonferroni correction for multiple comparisons (P <498  $0.05 / 6 = 8.33 \times 10^{-3}$ ). These findings highlight the subtle genetic interactions between 499 500 MAFLD and CVD, which underscores the potential for shared genetic pathways to 501 influence these complex diseases.

502

## 503 Genetic overlap analysis

The  $r_g$  is a vital metric that reflects the genetic relationship between trait pairs, 504 providing insights into their shared genetic architecture. Importantly, a  $r_g$  value close 505 506 to zero does not necessarily signify the absence of a genetic association between traits. 507 This apparent discrepancy can arise from various factors, such as the mixed effects of 508 homozygosity and reverse effects, or a lack of genetic overlap, which may mask the 509 true genetic relationships and lead to misleadingly low  $r_g$  values. Recognizing this limitation highlights a "missing dimension" in our understanding of genetic 510 511 connections between phenotypes. To enhance our understanding of genetic 512 interactions and address these challenges, advanced statistical methods, including 513 GPA and LAVA, have been employed by us.

514

515 The intricacies of the genetic relationships observed between MAFLD and CVDs, 516 particularly the surprising contrast between significant genetic overlap and weak 517 correlation in some cases, underscore the complexity of genetic interactions and the 518 importance of considering additional analytical dimensions. In our analysis of six trait 519 pairs, the MAFLD-AF pair was the only one that failed to meet the Bonferroni 520 correction threshold, indicating a lack of significant genetic overlap. Conversely, the MAFLD-CAD pair demonstrated the most significant genetic overlap, evidenced by a 521 P-value of  $7.12 \times 10^{-31}$ , aligning with LDSC results, which revealed the highest genetic 522 correlation ( $r_g = 0.627$ ,  $P = 5.18 \times 10^{-6}$ ). Although a significant genetic overlap was 523

identified between MAFLD and Stroke ( $P = 6.96 \times 10^{-6}$ ), the minimal PAR value (PAR 524  $= 7.00 \times 10^{-4}$ ) highlights a small proportion of pleiotropic SNPs. Furthermore, the weak 525 genetic correlation between MAFLD and Stroke ( $r_g = 0.627$ ,  $P = 3.98 \times 10^{-2}$ ) suggests 526 527 that the presence of multiple closely linked SNPs with independent or heterogeneous 528 impacts may obscure consistent effects, resulting in a correlation that falls short of 529 higher statistical confidence thresholds. This phenomenon, where broad genetic 530 overlap coexists with weak genetic correlation, implies that mixed effects may mask 531 the true genome-wide genetic correlation.

532

### 533 **Regional genetic correlation analysis**

LAVA evaluates genetic correlations within specific genomic regions and identifies 534 535 subtle genetic effects that might elude detection by LDSC. This capability is vital, as 536 genetic influences often vary across the genome, and the correlations between traits 537 can differ markedly by region. First, a univariate LAVA analysis was conducted by us with a strict threshold of  $P < 1 \times 10^{-4}$  to identify regions with strong genetic signals, 538 539 resulting in the identification of 2,336 significant regions. These regions were then 540 formed into 77 bivariate test sets for more detailed analysis. In the subsequent 541 bivariate LAVA analysis, we applied a looser significance threshold (P < 0.05), 542 identifying approximately 22 genomic regions showing genetic signals associated 543 with all trait pairs. Notably, our LAVA analysis revealed five key genetic regions 544 associated with MAFLD and stroke, including three negatively and two positively 545 correlated regions. This discovery of substantial genetic overlap starkly contrasts the

546	lack of significant genome-wide associations found using LDSC. This discrepancy
547	between the LAVA and LDSC results underscores the complex genetic architecture,
548	suggesting that regions with both positive and negative correlations may lead to a
549	heterogeneous distribution of genetic effects. Such complexity might mask genetic
550	signals when assessed on a genome-wide scale using LDSC. We then applied a
551	stricter threshold of $P < 6.49 \times 10-4$ to account for multiple comparisons. This led to
552	the identification of a significant region on chromosome 8, spanning from
553	125,453,321 to 126,766,827, showing a strong correlation between MAFLD and CAD
554	( $r_g s=0.509$ , $P=3.05\times10^{-6}$ ), aligns with the positive genetic correlation observed across
555	the genome by LDSC.

556

#### 557 Causal relationship linking MAFLD and CVDs

558 The observed genetic overlap between MAFLD and CVDs extends beyond mere 559 correlation, suggesting the presence of pleiotropy. However, determining whether this 560 pleiotropy is horizontal or vertical remains unresolved. To clarify this, we utilized the 561 LHC-MR approach, which sheds light on the bidirectional causal relationships 562 between MAFLD and CVD through vertical pleiotropy. Our findings revealed a significant positive causal effect of MAFLD on both AF and PAD, with odds ratios 563 (OR) of 1.11 ( $P = 2.36 \times 10^{-3}$ ) and 1.375 ( $P = 1.39 \times 10^{-4}$ ), respectively. These results 564 565 underscore MAFLD as a critical risk factor in the onset and development of both AF 566 and PAD, aligning with previous research that highlights MAFLD's role in increasing 567 the prevalence of these disorders. Notably, we found no evidence to suggest reverse

568 causality in these relationships.

569

### 570 Shared variants and functional annotation of MAFLDs and CVDs

571 To further dissect the complex genetic mechanisms between MAFLD and CVDs, we 572 utilized PLACO to identify significant pleiotropic variants indicative of horizontal 573 pleiotropy. This inquiry, through its meticulous analysis, unveiled a trove of 3,438 574 SNPs exhibiting significant pleiotropic influences. Subsequently, these SNPs 575 underwent a process of annotation, facilitated by the FUMA tool, which meticulously 576 delineated 49 distinct loci spanning 20 chromosomal regions, enriching our 577 understanding of the genetic landscape under scrutiny. Seven of the 49 loci identified 578 were novel and had not been previously associated with MAFLD or CVDs. Among 579 the 22 loci (44.9%), the selected effect alleles at the top SNPs within or near loci 580 demonstrated effect directions that were consistent with each other which means they may concurrently increase ADs and CVDs or diminish the risk of developing ADs and 581 582 CVDs. Notably, three loci, 22q13.31, 16q12.2, and 8q24.13, were associated with 583 more than half of the trait pairs analyzed. The chromosomal region 22q13.31, in particular, is implicated in five trait pairs, excluding MAFLD-Stroke, highlighting its 584 585 significance in the pleiotropic landscape. For example, SAMM50 located at 22q13.31, 586 studies have shown that SAMM50 gene polymorphisms are associated with the occurrence and severity of fatty liver disease, which may be related to reduced fatty 587 acid oxidation caused by SAMM50 deficiency<sup>40</sup>. Although there is no direct evidence 588 589 linking SAMM50 to cardiovascular disease, its potential effects on heart development

590	and function by regulating mitochondrial autophagy may influence cardiovascular
591	disease risk <sup>41</sup> . Moreover, the FTO gene, located in the 16q12.2 region, is another gene
592	of interest due to its impact on energy intake and expenditure, potentially increasing
593	susceptibility to both MAFLD and CVDs <sup>42,43</sup> . Moreover, the <i>TRIB1</i> gene, located at
594	8q24.13, plays a critical role in regulating lipid metabolism. It influences downstream
595	signaling pathways such as PI3K-AKT and MAPK, which promote the accumulation
596	of liver lipids and increase the risk of MAFLD <sup>44,45</sup> . Additionally, polymorphisms in
597	the TRIB1 gene have been linked to an increased risk of CAD and Stroke. Specifically,
598	the A allele at rs2954029 has been significantly associated with these conditions;
599	individuals carrying the A allele exhibit a higher risk of both CAD and stroke <sup>46</sup> .

600

601 Functional annotation via FUMA identified 24 intronic SNPs, 14 intergenic SNPs, 602 and 5 exonic SNPs. For example, the 22q13.31 region includes the exonic SNP rs1007863, which showed significant eQTL associations in several tissues: adipose 603 subcutaneous ( $P = 2.38 \times 10^{-6}$ ), adipose visceral omentum ( $P = 2.16 \times 10^{-15}$ ), whole 604 blood ( $P = 3.57 \times 10^{-5}$ ), artery aorta ( $P = 3.57 \times 10^{-5}$ ), and artery tibial ( $P = 1.42 \times 10^{-12}$ ). 605 606 Notably, the P-value for adipose visceral omentum was used as the P-value for this region in MAFLD-AF for PLACO results, indicating that this P-value is considered 607 608 the most appropriate or representative indicator, suggesting that visceral tissues are 609 importantly associated with this trait pair. Seven of all pleiotropic SNPs were 610 identified as potentially deleterious, with a CADD score greater than 12.37. Notably, rs28929474 exhibited the highest CADD score of 20.2, suggesting its potential 611

612	association with the development of MAFLD and CAD and its deleterious effects.
613	Furthermore, based on RDB scores, two SNPs were found to potentially impact
614	transcription factor binding, with rs10401969 showing the most significant effect
615	(RBD = 1f). Further colocalization analysis revealed evidence of colocalization in $13$
616	of the 49 pleiotropic loci (PPH4 $>$ 0.7). Notably, the 16q12.2 region has demonstrated
617	a robust colocalization signal across all four trait pairs it encompasses (with a
618	posterior probability of heterogeneity, PPH4, ranging from 0.766 to 0.890).

619

#### Gene-level annotation of MAFLD and CVDs 620

621 Using MAGMA, we identified 34 potential pleiotropic genes (28 of which are unique) 622 between MAFLD and CVDs after Bonferroni correction, which is situated on or 623 overlaps with 49 previously identified pleiotropic loci. Among these, 2 are novel 624 unique genes, 3 have newly unique been associated with CVDs, and 23 are newly unique implicated in MAFLD. Notably, three genes-SAMM50, PNPLA3, and 625 626 FTO—were detected in two or more trait pairs. Further, of the genes identified by 627 MAGMA, 32 were corroborated by FUMA's locus mapping. The pervasive impact of 628 SAMM50 across multiple traits underscores its significance and makes it a primary focus of our ongoing investigation. 629

630

We performed tissue-specific analyses employing LDSC-SEG to identify the tissues 631 632 associated with each disease. After adjusting for multiple comparisons using the FDR 633 method, significant associations were observed solely with CVDs. Specifically, for AF,

634 the auricle and the left ventricle were identified as the primary tissues driving the 635 condition, suggesting that functional changes in these areas may play a crucial role in 636 its development and maintenance. Similarly, in CAD, the predominant tissues 637 associated with the disease were located in arterial regions, including the aorta, 638 coronary artery, and anterior tibial artery, with the anterior tibial artery demonstrating 639 the most significant impact. Unfortunately, while MAFLD showed enrichment in the 640 anterior cingulate cortex, cerebral cortex, and frontal cortex, these did not meet the 641 significant threshold for correction. In all, afte integrating the results of tissue enrichment analysis with tissues commonly implicated in clinical practice for these 642 643 conditions, we finally selected 10 tissues for subsequent analysis.

644

645 Given the limitations of MAGMA, which assigns SNPs based solely on proximity to 646 genes and may overlook the effects of distant gene regulation, we employed 647 e-MAGMA to overcome these deficiencies. By integrating eQTL data from 10 648 distinct tissues, e-MAGMA enabled us to identify 161 tissue-specific genes, including 649 59 that were unique. Notably, IRAK1BP1, ATP13A1, SAMM50 and NME7 were 650 identified in more than half of the trait pairs. *IRAK1BP1* exhibits high specificity to 651 nine tissues except EBV-transformed lymphocytes and has not previously been 652 associated with MAFLD or any CVDs. However, its involvement in inflammation 653 suggests a potential role in these diseases. Our findings were further validated using 654 FUMA's GTExV8 data through e-MAGMA, confirming the identification of 78 655 tissue-specific genes, including SAMM50 at 22q13.31. Subsequent TWAS analysis of

656	the original GWAS results was used to validate the EMAGMA analysis, and 300
657	tissue-specific genes were identified as new genes for MAFLD and 185 as new genes
658	for CVDs.

659

Finally, 17 pleiotropic genes (14 unique) were identified by MAGMA and e-MAGMA. *SAMM50* at 22q13.31 was the only gene that appeared in multiple trait pairs (except
for MAFLD-PAD and MAFLD-Stroke), while other genes appeared only in single
trait pairs.

664

## 665 Functional enrichment analysis of pleiotropic genes in MAFLD and CVDs

666 Understanding how identified genes collectively fulfill specific biological functions 667 through shared pathways enhances our ability to derive meaningful interpretations 668 from genomic data. The tool ToppFun assists in mapping these genes to their 669 respective enrichment pathways and biological processes, which can reveal the 670 activity levels or enrichment of certain pathways. Notably, three pathways were 671 significantly enriched: membrane organization, endoplasmic reticulum tubular network organization, and the establishment of protein localization to the membrane. 672 673 Protein localization is critical in the accumulation of lipid droplets near mitochondria; 674 it helps protect mitochondrial function by sequestering toxic lipids. This protective 675 mechanism is crucial for managing lipid accumulation in the liver and other tissues, where excessive lipid buildup can lead to MAFLD and CVDs<sup>47,48</sup>. Proper protein 676 677 localization, therefore, plays a pivotal role in mitigating lipid toxicity and maintaining

678 cellular balance, thereby reducing the risk of both MAFLD and CVD.

679

#### 680 Discussion

681 This genome-wide pleiotropic association study offers compelling evidence of a 682 shared genetic architecture and mechanisms between MAFLD and six major CVDs. 683 We observed moderate to strong genome-wide genetic associations between MAFLD 684 and four CVDs—CAD, HF, PAD, and VTE—with notable genetic overlap in all but 685 the MAFLD-AF trait pair. MR analysis provided evidence of causal relationships for 686 two trait pairs, underscoring the presence of vertical pleiotropy. Additionally, at the 687 SNP level, our cross-trait analysis pinpointed 49 pleiotropic loci, 13 demonstrating 688 strong evidence of colocalization. Further analysis at the gene level through MAGMA 689 and e-MAGMA identified 45 (34 unique) significant position-specific pleiotropic 690 genes and 161 (59 unique)tissue-specific pleiotropic genes, including 17 overlapping 691 pleiotropic genes (14 unique because SAMM50 was identified in 4 trait pairs). 692 Moreover, at the biological pathway level, protein localization to membrane signaling 693 pathways was identified as potentially pivotal in the co-pathogenesis of MAFLD and CVD. These insights not only deepen our understanding of their intertwined genetic 694 695 etiology but also illuminate potential targets for therapeutic intervention and 696 preventive strategies.

697

In our study, bivariate LDSC revealed extensive positive genetic correlations betweenMAFLD and six major CVDs, among which only four trait pairs (including

700 MAFLD-CAD, MAFLD-HF, MAFLD-PAD, and MAFLD-VTE) passed the 701 Bonferroni correction. Further analysis using the GPA method demonstrated 702 significant genetic overlap for all pairs except MAFLD with AF, underscoring the 703 shared genetic underpinnings of these conditions. Interestingly, although no 704 significant genome-wide genetic correlation was detected between MAFLD and 705 stroke, substantial genetic overlap suggested the presence of complex genomic 706 interactions, which was also confirmed by local genetic correlations of LAVA. In the 707 MAFLD-stroke pair, we identified loci with mixed effect directions—two positively 708 and three negatively correlated—suggesting that local mixed effects might underlie 709 the non-significant genome-wide genetic correlation, potentially driven by a range of pleiotropic variants<sup>11</sup>. Additionally, despite the lack of a significant association 710 711 between MAFLD and AF in both LDSC and GPA analyses, our bivariate LAVA under 712 a loose threshold indicated a positive regional genetic correlation between the two. 713 Overall, our findings confirm that MAFLD and CVDs share substantial heritability 714 and genetic components, elucidating the genetic basis of their high comorbidity.

715

The shared genetic basis between MAFLD and CVD is primarily driven by horizontal and vertical pleiotropy (i.e., causal relationships). We employed the LHC-MR method to investigate potential causal links between MAFLD and 6 major CVDs. Our analysis revealed that genetically predicted MAFLD is causally associated with an increased risk of AF and PAD. These findings are consistent with prior epidemiological evidence. A meta-analysis confirmed an association between

722	MAFLD and an increased risk of AF <sup>49</sup> . Concurrently, a separate cohort study
723	observed a high prevalence of PAD among MAFLD patients over 40 years old in the
724	United States during a 13-year follow-up <sup>50</sup> . Conversely, we found no established
725	causal relationship between MAFLD and HF or Stroke, nor was a reverse causal
726	relationship between MAFLD and CVD supported. This contrasts with earlier MR
727	analyses that reported a positive causal relationship between MAFLD and both $\mathrm{HF}^{15}$
728	and CAD <sup>14</sup> , which suggested a 15% increase in CAD incidence per unit increase in
729	MAFLD. These discrepancies may arise from limitations in previous studies, such as
730	potential genetic confounders and smaller sample sizes, which could impact the
731	reliability of the exposure-outcome relationship. LHC-MR analysis is particularly
732	effective at generating potential causal effects by excluding confounding factors, even
733	in the face of unmeasured confounding. Leveraging extensive sample data and
734	advanced methodologies, our study provided more robust and reliable causal effect
735	estimates. Our study only provides partial evidence for vertical pleiotropy, suggesting
736	that the shared genetic basis between MAFLD and CVD is primarily driven by
737	horizontal pleiotropy.

738

Horizontal pleiotropy analysis further elucidated the common genetic architecture between MAFLD and CVD by discovering pleiotropic variants and loci, pleiotropic genes, and biological pathways between the two. Further investigation through horizontal pleiotropy analysis has confirmed their extensive comorbidity, identifying widespread pleiotropic variants across several key loci, such as 22q13.31, 16q12.2,

744	and 8q24.13, which are prominently associated with more than half of the trait pairs
745	analyzed. Notably, the locus at 16q12.2-associated with all trait pairs except
746	MAFLD-CAD and MAFLD-Stroke-maps to the FTO gene. This gene plays a
747	critical role in lipid metabolism by enhancing oxidative stress and increasing
748	lipogenesis in hepatocytes, thereby exacerbating MAFLD progression <sup>51</sup> . Moreover,
749	according to a meta-analysis of 10 observational studies (19,153 CVD cases and
750	103,720 controls), variants in the FTO gene have been shown to significantly elevate
751	CVD risk, independent of BMI and other conventional risk factors <sup>52</sup> . Moreover, in a
752	large prospective longitudinal study of Type 2 diabetes (T2D) patients, variants in the
753	FTO gene were also found to increase the risk of myocardial infarction and
754	cardiovascular death by influencing a dyslipidemic phenotype typical of insulin
755	resistance <sup>53</sup> . The above evidence suggests that the lipid metabolism process can be
756	significantly changed by affecting the expression of the FTO gene, thereby improving
757	MAFLD and reducing the risk of cardiovascular death.

758

In our gene-level analysis using MAGMA and e-MAGMA, we identified significant pleiotropic genes at the 22q13.31 locus, including patatin-like phospholipase-domain containing protein 3 (*PNPLA3*) and sorting and assembly machinery component 50 (*SAMM50*). These genes play crucial roles in the comorbidity between MAFLD and CVDs. *PNPLA3*, which exhibits weak hydrolytic activity towards glycerolipids, has been linked to the development of MAFLD and CVDs, excluding PAD and Stroke. This gene is associated with a missense variant closely linked to triacylglycerol (TAG)

766	accumulation in the liver—a major genetic risk factor for steatotic liver diseases <sup>54,55</sup> .
767	PNPLA3 competitively displaces adipose triglyceride lipase (ATGL) from lipid
768	droplets, reducing lipolytic activity and promoting the progression of MAFLD <sup>54</sup> .
769	Intriguingly, a GWAS meta-analysis revealed that the PNPLA3 G-allele rs738409
770	offers modest protection against CAD by reducing triglyceride breakdown in the liver,
771	thus affecting the secretion of very low-density lipoprotein particles and the
772	development of atherosclerosis <sup>56</sup> . Additionally, our e-MAGMA analysis identified
773	SAMM50 at this locus as influencing most trait pairs. As an essential component of
774	the Sorting and Assembly Machinery (SAM) complex on the outer mitochondrial
775	membrane, SAMM50 is vital for $\beta$ -barrel protein biogenesis and interacts directly with
776	the translocator of the outer mitochondrial membrane (TOM) complex <sup>41</sup> . It plays a
777	significant role in fatty acid $\beta$ -oxidation and, when deficient, can lead to intracellular
778	lipid accumulation, exacerbating MAFLD <sup>40</sup> . Moreover, SAMM50's involvement in
779	mitochondrial dysfunction may impair the removal of reactive oxygen species (ROS),
780	further contributing to the progression of MAFLD <sup>57</sup> and increasing susceptibility to
781	HF by impairing mitochondrial function <sup>41</sup> . This mitochondrial pathway regulated by
782	SAMM50 offers a theoretical basis for the observed comorbidity between MAFLD
783	and HF in our study, underscoring the potential for targeted therapies at this genetic
784	locus.

785

In our pathway-level analysis, we discovered a crucial role for the gene *SAMM50* in
mediating protein localization to membranes, a process integral to the pathogenesis of

788 MAFLD. This protein localization is especially important in how lipid droplets 789 accumulate near mitochondria, which may protect mitochondrial function by 790 sequestering toxic lipid species. Proteins that migrate to these lipid droplets at 791 membrane contact sites are prime candidates for facilitating this protective mechanism $^{47,48}$ . In the liver, an excessive influx of lipids leads to the accumulation of 792 triglyceride (TG)-rich lipid droplets, a hallmark of MAFLD<sup>47</sup>. Variations in genes 793 794 associated with lipid droplet formation, such as PNPLA3, acting as both 795 phospholipase and acyl transfer enzyme, is an important regulating factor for TG. It limits the activity of triglyceride hydrolases, leading to TG accumulation in the liver, 796 thus predisposing to MAFLD<sup>58</sup>. Moreover, when lipid droplets amass in peripheral 797 798 organs, the overflow of toxic lipids can contribute to CVDs. ATGL plays a pivotal role 799 in this context by hydrolyzing TG within these droplets. It activates the 800 PPAR $\alpha$ /peroxisome proliferator-activated receptor- $\gamma$  coactivator 1 (*PGC1*) complex in 801 cardiomyocytes. A deficiency in cardiac ATGL leads to reduced PGC1 expression, 802 resulting in mitochondrial dysfunction and lipid accumulation, which can progress to HF<sup>59</sup>. In conclusion, the localization of contact site proteins related to lipid droplets is 803 instrumental in preventing lipid overflow and safeguarding mitochondrial function. 804 805 This mechanism significantly reduces the risk of both MAFLD and CVD by 806 maintaining crucial cellular balances and interactions.

807

808 Our study has several limitations. First, our study population was confined to 809 individuals of European ancestry, necessitating further research across other ethnic

810	groups to determine the universal applicability of our findings. Second, the datasets
811	used for MAFLD and CVD included some cases with existing or potential co-morbid
812	conditions, which may have biased our investigation of genetic overlap. Third, our
813	analysis was limited to common genetic variants, highlighting the need for future
814	studies to explore the impact of rare variants, which may also significantly influence
815	the high comorbidity observed between MAFLD and CVD. Finally, while we
816	reported some statistically significant findings, further investigation is required to
817	assess their clinical relevance and implications.

818

819 In summary, our study demonstrates extensive genetic overlap, partial genetic 820 correlation, and causal relationships between MAFLD and six major CVDs. 821 Identification of the pleiotropic gene, SAMM50, at pleiotropic risk loci 22q13.31, 822 shared between MAFLD and CVD, suggesting a common biological mechanism, 823 namely the establishment of protein localization to the membrane, uncovering 824 indications of shared genetic foundation for MAFLD and CVDs. This research 825 enhances the shared genetic map of these diseases and offers new perspectives on 826 preventing and treating their co-morbidities.

### 828 Abbreviations

829	AF (atrial fibrillation) ApoC3 (apolipoprotein C3) ATGL (adipose triglyceride lipase)
830	CVDs (cardiovascular diseases) CAD (coronary artery disease ) CRP (C-Reactive
831	Protein) CADD (Combined Annotation-Dependent Depletion) e-MAGMA
832	(eQTL-informed MAGMA) eMERGE (Electronic Medical Records and Genomics)
833	EstBB (Estonian Biobank) FUMA (Functional Mapping and Annotation) FDR (false
834	discovery rate) GPA (Genetic Analysis incorporating Pleiotropy and Annotation)
835	GWAS (genome-wide association studies) $h^2_{SNP}$ (SNP-based heritability) HF (heart
836	failure) HUNT (Health Study Nord-Trøndelag) HERMES (Heart Failure Molecular
837	Epidemiology for Therapeutic Targets) IVW (Inverse Variance Weighting) IL-1
838	(interleukin-1) LDSC (linkage disequilibrium score regression) LD (linkage
839	disequilibrium) LDSC-SEG (LDSC applied to specifically expressed genes) LRT
840	(likelihood ratio test) LAVA (Local Analysis of [co]Variant Annotation) LHC-MR
841	(Latent Heritable Confounder Mendelian randomization) MAFLD (metabolic
842	dysfunction-associated fatty liver disease) MR (Mendelian Randomization) MGI
843	(Michigan Genome Initiative) MAF (minor allele frequency) MHC (major
844	histocompatibility complex) MAGMA (Multi-marker Analysis of GenoMic
845	Annotation) NAFLD (Non-alcoholic fatty liver disease) OR (odds ratios) PAD
846	(peripheral artery disease) PLACO (Pleiotropic Analysis under a Composite Null
847	Hypothesis) RDB (RegulomeDB) PP (posterior probabilities) PNPLA3 (patatin-like
848	phospholipase-domain containing protein 3) PGC1 (PPARα/peroxisome
849	proliferator-activated receptor- $\gamma$ coactivator 1) ROS (reactive oxygen species) SNPs

850	(single nucleotide polymorphisms) SAMM50 (sorting and assembly machinery
851	component 50) SAM (Sorting and Assembly Machinery) TWAS (transcriptome-wide
852	association study) ToppFun (ToppGene functional annotation tool) TFBS
853	(transcription factor binding sites) T2D (Type 2 diabetes) TAG (triacylglycerol) TOM
854	(translocator of the outer mitochondrial membrane) TG (triglyceride) UKB (UK
855	Biobank) VTE (venous thromboembolism)

856

#### 857 Acknowledgements

We would like to thank all GWAS authors who provided summary statistics for this 858 859 study. We thank the Electronic Medical Records and Genomics (eMERGE) Network, 860 the UK Biobank (UKB), the Estonian Biobank (EstBB), and the FinnGen Consortium 861 for providing us with data on MAFLD, without whom this work would not have been 862 possible. We would also like to thank the Health Study Nord-Trøndelag (HUNT), 863 deCODE, Michigan Genome Initiative (MGI), DiscovEHR, UKB, and AFGen 864 consortium for providing AF data; the CARDIoGRAMplusC4D and UKB consortium for providing CAD data; the deCODE for providing VTE data; the Heart Failure 865 866 Molecular Epidemiology for Therapeutic Targets (HERMES) consortium for providing HF data; the Cardiovascular Disease Knowledge Portal (CVDKP) website 867 868 for providing PAD data; and the GIGASTROKE consortium for providing stroke 869 data.

870

#### 871 **References**

- [1] Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et
- al. A new definition for metabolic dysfunction-associated fatty liver disease: An
- international expert consensus statement. J Hepatol 2020; 73: 202-9.
- 875 [2] Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed
- 876 Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020;
- 877 158: 1999-2014.e1.
- 878 [3] Sanyal AJ, Castera L, Wong VW. Noninvasive Assessment of Liver Fibrosis in
- NAFLD. Clin Gastroenterol Hepatol 2023; 21: 2026-39.
- 880 [4] Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related
- mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.
- [5] Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to
- cardiovascular disease. Mol Metab 2020; 42: 101092.
- [6] Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and
- cardiovascular diseases: a clinical review. Clin Res Cardiol 2021; 110: 921-37.
- 886 [7] Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver
- disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016;
- **888** 65: 589-600.
- [8] Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al.
- 890 Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic
- steatohepatitis from cardiovascular disease. Hepatology 2015; 61: 506-14.
- [9] Brouwers M, Simons N, Stehouwer CDA, Koek GH, Schaper NC, Isaacs A.

893	Relationship	Between	Nonalcoholic	Fatty	Liver	Disease	Susceptibility	Genes	and

- 894 Coronary Artery Disease. Hepatol Commun 2019; 3: 587-96.
- [10] Fang Z, Jia S, Mou X, Li Z, Hu T, Tu Y, et al. Shared genetic architecture and
- causal relationship between liver and heart disease. iScience 2024; 27: 109431.
- [11] Hindley G, Frei O, Shadrin AA, Cheng W, O'Connell KS, Icick R, et al. Charting
- the Landscape of Genetic Overlap Between Mental Disorders and Related Traits
- Beyond Genetic Correlation. Am J Psychiatry 2022; 179: 833-43.
- 900 [12]Perry BI, Bowker N, Burgess S, Wareham NJ, Upthegrove R, Jones PB, et al.
- 901 Evidence for Shared Genetic Aetiology Between Schizophrenia, Cardiometabolic, and
- 902 Inflammation-Related Traits: Genetic Correlation and Colocalization Analyses.
- 903 Schizophr Bull Open 2022; 3: sgac001.
- 904 [13] Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy
- in Mendelian randomization studies. Hum Mol Genet 2018; 27: R195-r208.
- 906 [14] Ren Z, Simons P, Wesselius A, Stehouwer CDA, Brouwers M. Relationship
- 907 between NAFLD and coronary artery disease: A Mendelian randomization study.
- 908 Hepatology 2023; 77: 230-8.
- 909 [15]Peng H, Wang S, Wang M, Ye Y, Xue E, Chen X, et al. Nonalcoholic fatty liver
- 910 disease and cardiovascular diseases: A Mendelian randomization study. Metabolism
  911 2022; 133: 155220.
- 912 [16]Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, et al. Electronic
  913 health record-based genome-wide meta-analysis provides insights on the genetic
  914 architecture of non-alcoholic fatty liver disease. Cell reports Medicine 2021; 2:

915	100437.
915	100437.

916	[17]Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et
917	al. Biobank-driven genomic discovery yields new insight into atrial fibrillation
918	biology. Nature genetics 2018; 50: 1234-9.
919	[18] Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery
920	and systematic characterization of risk variants and genes for coronary artery disease
921	in over a million participants. Nature genetics 2022; 54: 1803-15.
922	[19]Ghouse J, Tragante V, Ahlberg G, Rand SA, Jespersen JB, Leinøe EB, et al.
923	Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction
924	equivalent to monogenic forms of venous thromboembolism. Nature genetics 2023;
925	55: 399-409.
926	[20]Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al.
927	Genome-wide association and Mendelian randomisation analysis provide insights into
928	the pathogenesis of heart failure. Nature communications 2020; 11: 163.
929	[21]van Zuydam NR, Stiby A, Abdalla M, Austin E, Dahlström EH, McLachlan S, et
930	al. Genome-Wide Association Study of Peripheral Artery Disease. Circulation
931	Genomic and precision medicine 2021; 14: e002862.
932	[22] Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, et al. Stroke
933	genetics informs drug discovery and risk prediction across ancestries. Nature 2022;

**934** 611: 115-23.

935 [23] Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A

global reference for human genetic variation. Nature 2015; 526: 68-74.

- 937 [24]Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al.
- 938 LD Score regression distinguishes confounding from polygenicity in genome-wide
- association studies. Nature genetics 2015; 47: 291-5.
- 940 [25]Zhang Y, Qi G, Park JH, Chatterjee N. Estimation of complex effect-size
- 941 distributions using summary-level statistics from genome-wide association studies
- across 32 complex traits. Nature genetics 2018; 50: 1318-26.
- 943 [26] Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, et al.
- 944 Heritability enrichment of specifically expressed genes identifies disease-relevant
- tissues and cell types. Nature genetics 2018; 50: 621-9.
- 946 [27]Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis:
- multitissue gene regulation in humans. Science (New York, NY) 2015; 348: 648-60.
- 948 [28] Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to
- prioritizing GWAS results by integrating pleiotropy and annotation. PLoS genetics
- 950 2014; 10: e1004787.
- 951 [29] Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework
- for local genetic correlation analysis. Nature genetics 2022; 54: 274-82.
- 953 [30]Darrous L, Mounier N, Kutalik Z. Simultaneous estimation of bi-directional
- causal effects and heritable confounding from GWAS summary statistics. Naturecommunications 2021; 12: 7274.
- 956 [31]Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite
- null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate
- 958 Cancer. PLoS genetics 2020; 16: e1009218.

959	[32] Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
960	annotation of genetic associations with FUMA. Nature communications 2017; 8:
961	1826.

- 962 [33]Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general
- framework for estimating the relative pathogenicity of human genetic variants. Nature
- 964 genetics 2014; 46: 310-5.

- - - - - - -

- 965 [34]Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al.
- 966 Annotation of functional variation in personal genomes using RegulomeDB. Genome
- 967 research 2012; 22: 1790-7.
- 968 [35] Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
- 969 variants from high-throughput sequencing data. Nucleic acids research 2010; 38:970 e164.
- 971 [36] de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set
- analysis of GWAS data. PLoS computational biology 2015; 11: e1004219.
- 973 [37]Gerring ZF, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an
- 974 eQTL-informed method to identify risk genes using genome-wide association study
- summary statistics. Bioinformatics (Oxford, England) 2021; 37: 2245-9.
- 976 [38]Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate
  977 causal variants by statistical fine-mapping. Nature reviews Genetics 2018; 19:
  978 491-504.
- 979 [39]Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list
  980 enrichment analysis and candidate gene prioritization. Nucleic acids research 2009;

- 981 37: W305-11.
- 982 [40]Li Z, Shen W, Wu G, Qin C, Zhang Y, Wang Y, et al. The role of SAMM50 in
- non-alcoholic fatty liver disease: from genetics to mechanisms. FEBS Open Bio 2021;
- 984 11: 1893-906.
- 985 [41]Xu R, Kang L, Wei S, Yang C, Fu Y, Ding Z, et al. Samm50 Promotes
- 986 Hypertrophy by Regulating Pink1-Dependent Mitophagy Signaling in Neonatal
- 987 Cardiomyocytes. Front Cardiovasc Med 2021; 8: 748156.
- 988 [42]Patnaik D, Jena AB, Kerry RG, Duttaroy AK. In silico profiling of
- nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on
- the treatment of non-alcoholic fatty liver disease. Lipids Health Dis 2023; 22: 17.
- 991 [43]Xu ZY, Jing X, Xiong XD. Emerging Role and Mechanism of the FTO Gene in
- 992 Cardiovascular Diseases. Biomolecules 2023; 13.
- 993 [44]Bauer RC, Yenilmez BO, Rader DJ. Tribbles-1: a novel regulator of hepatic lipid
- metabolism in humans. Biochem Soc Trans 2015; 43: 1079-84.
- 995 [45]Zhang T, Tan P, Wang L, Jin N, Li Y, Zhang L, et al. RNALocate: a resource for
- 996 RNA subcellular localizations. Nucleic acids research 2017; 45: D135-d8.
- 997 [46] Jiang J, Chen X, Li C, Du X, Zhou H. Polymorphisms of TRIB1 genes for
- coronary artery disease and stroke risk: A systematic review and meta-analysis. Gene
  2023; 880: 147613.
- 1000 [47]Krahmer N, Najafi B, Schueder F, Quagliarini F, Steger M, Seitz S, et al.
- 1001 Organellar Proteomics and Phospho-Proteomics Reveal Subcellular Reorganization in
- 1002 Diet-Induced Hepatic Steatosis. Dev Cell 2018; 47: 205-21.e7.

1003	[48]Nguyen	TB,	Louie	SM,	Daniele	JR,	Tran	Q,	Dillin	А,	Zoncu	R,	et	al.
------	------------	-----	-------	-----	---------	-----	------	----	--------	----	-------	----	----	-----

- 1004 DGAT1-Dependent Lipid Droplet Biogenesis Protects Mitochondrial Function during
- 1005 Starvation-Induced Autophagy. Dev Cell 2017; 42: 9-21.e5.
- 1006 [49] Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of
- 1007 cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic
- review and meta-analysis. Eur J Prev Cardiol 2022; 29: 938-46.
- 1009 [50] Ciardullo S, Bianconi E, Cannistraci R, Parmeggiani P, Marone EM, Perseghin G.
- 1010 Peripheral artery disease and all-cause and cardiovascular mortality in patients with
- 1011 NAFLD. J Endocrinol Invest 2022; 45: 1547-53.
- 1012 [51]Guo J, Ren W, Li A, Ding Y, Guo W, Su D, et al. Fat mass and obesity-associated
- 1013 gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. Dig
- 1014 Dis Sci 2013; 58: 1004-9.
- 1015 [52]Liu C, Mou S, Pan C. The FTO gene rs9939609 polymorphism predicts risk of
- 1016 cardiovascular disease: a systematic review and meta-analysis. PLoS One 2013; 8:1017 e71901.
- 1018 [53]Doney AS, Dannfald J, Kimber CH, Donnelly LA, Pearson E, Morris AD, et al.
- 1019 The FTO gene is associated with an atherogenic lipid profile and myocardial
- 1020 infarction in patients with type 2 diabetes: a Genetics of Diabetes Audit and Research
- 1021 Study in Tayside Scotland (Go-DARTS) study. Circ Cardiovasc Genet 2009; 2: 255-9.
- 1022 [54] Witzel HR, Schwittai IMG, Hartmann N, Mueller S, Schattenberg JM, Gong XM,
- 1023 et al. PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with
- 1024 ATGL. Cells 2022; 12.

1025	[55]Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3
1026	protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem
1027	2011; 286: 37085-93.

- 1028 [56] Simons N, Isaacs A, Koek GH, Kuč S, Schaper NC, Brouwers M. PNPLA3,
- 1029 TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease. Gastroenterology
- 1030 2017; 152: 912-3.
- 1031 [57]Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al.
- 1032 Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and
- 1033 PARVB genes are associated with development and progression of nonalcoholic fatty
- liver disease in Japan. Hum Genet 2013; 132: 783-92.
- 1035 [58] Dai G, Liu P, Li X, Zhou X, He S. Association between PNPLA3 rs738409
- 1036 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and
- severity: A meta-analysis. Medicine 2019; 98: e14324.
- 1038 [59]Krahmer N, Farese RV, Jr., Walther TC. Balancing the fat: lipid droplets and
- 1039 human disease. EMBO Mol Med 2013; 5: 973-83.

		Genetic cor	Genetic overlap				
Trait pair	Genetic correlation (SE)	<i>P</i> value for LDSC	Intercept (SE)	P value for intercept	PM 11	PAR <sup>b</sup>	<i>P</i> value for GPA
MAFLD-AF	0.1381 (0.0891)	0.121	0.0080 (0.0053)	0.131	0.0000	0.0004	9.55×10 <sup>-2</sup>
MAFLD-CAD <sup>c.d</sup>	0.6266 (0.1375)	5.18×10 <sup>-6</sup>	0.0018 (0.0059)	0.760	0.0036	0.0424	7.12×10 <sup>-31</sup>
MAFLD-HF <sup>c.d</sup>	0.5725 (0.1576)	3.00×10 <sup>-4</sup>	0.0058 (0.0045)	0.197	0.0001	0.0010	1.12×10 <sup>-11</sup>
MAFLD-PAD <sup>c.d</sup>	0.6259 (0.2099)	2.90×10 <sup>-3</sup>	0.0075 (0.0053)	0.157	0.0001	0.0029	1.32×10 <sup>-03</sup>
MAFLD-Stroke <sup>d</sup>	0.2783 (0.1353)	3.98×10 <sup>-2</sup>	0.0057 (0.0045)	0.205	0.0001	0.0007	6.96×10 <sup>-6</sup>
MAFLD-VTE <sup>c.d</sup>	0.4844 (0.1220)	7.19×10 <sup>-5</sup>	0.0025 (0.0051)	0.624	0.0002	0.0025	4.66×10 <sup>-10</sup>

Table 1.	Genetic	Correlation	and	Genetic	Overlap	Estimations	Between	6
Pairwise	Traits							

Note:

a. Genetic correlation and genetic overlap were estimated by LDSC and GPA methods, respectively. Bonferroni-corrected significance threshold was set at  $P \square < \square 8.33 \times 10^{-3}$  (0.05/6), producing a final union set of 5 pairwise traits with significant genetic correlation or genetic overlap for subsequent analysis.

b. We introduced PAR as PM 11 / (PM 10 + PM 01 + PM 11) to represent the proportion of pleiotropic single-nucleotide variations (SNPs) associated with both traits against the proportion of SNPs associated with at least 1 trait.

c. Pairwise trait with significant genetic correlation.

d. Pairwise trait with significant genetic overlap.

Abbreviations: MAFLD, Metabolic dysfunction-Associated fatty liver disease; AF, Atrial fibrillation; CAD, Coronary artery disease; HF, Heart failure; PAD, Peripheral artery disease; VTE, Venous thromboembolism; LDSC, linkage disequilibrium score regression; GPA, genetic analysis incorporating pleiotropy and annotation method; PAR, pleiotropy association ratio; PM 11, proportion of genetic variants associated with both traits.

#### **Figure legends**

# Figure 1. Metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases estimated by local genetic correlation.

LAVA volcano plots showing local genetic correlation coefficients (local- $r_gs$ , y-axis) for MAFLD and CVDs with -log10 *p*-values for each trait pair of analyses for each locus. Loci above the horizontal line are significant at *P* < 0.05 (negative correlation for blue dots, positive correlation for red dots). Larger points with black circles indicate loci significantly associated after Bonferroni correction (*P* =  $6.49 \times 10^{-4} = 0.05$  / 77). LAVA-estimated local-rgs is shown on the blue-red scale. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

Figure 2. Inference of bidirectional causal relationship between metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.

Forest plots of the causal relationship between MAFLD and six major CVDs using the LHC-MR method. The estimates presented in the forest plot were obtained using the LHC-MR method. A positive association is indicated by the odd ratio (OR > 1), while a negative association is indicated by OR < 1. The results of forward causality from the LHC-MR method are in the up panel, and the results of reverse causality from the LHC-MR method are in the down panel. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

# Figure 3. Manhattan plots for the PLACO results of metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.


Manhattan reflect chromosomal position (x-axis) plots and negative log10-transformed P-values (y-axis) for each SNP. The horizontal dashed red line indicates the genome-wide significant P-value of  $-\log 10$  (5×10<sup>-8</sup>). The r<sup>2</sup> threshold for defining independent significant SNPs was set to 0.2, and the maximum distance between LD blocks merged into one locus was set to 500 kb. The independent genome-wide significant associations with the smallest P-value (Top lead SNP) are encircled in a colorful circle. Only SNPs shared across all summary statistics were included. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

# Figure 4. The overall situation of the pleiotropy association between metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.

A circular dendrogram showing the shared genes between MAFLD (center circle) and each of six CVDs (first circle), resulting in six pairs. A total of 49 shared loci were identified across six trait pairs (third circle), mapped to 45 nominally significant pleiotropic genes (34 were Bonferroni-corrected significant) identified by

multimarker analysis of GenoMic annotation (MAGMA). For the trait pairs with more than three pleiotropic genes, we only showed the top 3 pleiotropic genes according to the prioritization of candidate pleiotropic genes (fourth circle). MAFLD, metabolic dysfunction-associated fatty liver disease; AF, Atrial fibrillation; CAD, Coronary artery disease; VTE, Venous thromboembolism; HF, Heart failure; PAD, Peripheral artery disease.






## Figure 2.


Exposure	Outcome	OR (95% CI)		P value
NAFLD	AF	1.110 (1.043-1.177)	(INI	2.36e-03
NAFLD	CAD	1.368 (1.121-1.615)	<b></b>	1.31e-02
NAFLD	HF	1.003 (0.883-1.123)	H	9.67e-01
NAFLD	PAD	1.374 (1.211-1.537)		1.39e-04
NAFLD	VTE	1.307 (1.099–1.515)		1.13e-02
NAFLD	Stroke	1.281 (-0.246-2.808)		7.51e-01
AF	NAFLD	1.014 (0.969-1.059)	in the	5.55e-01
CAD	NAFLD	1.102 (1.065-1.139)	-	6.30e-07
HF	NAFLD	1.128 (0.995-1.261)		7.61e-02
PAD	NAFLD	1.039 (0.965-1.113)	He-I	3.11e-01
VTE	NAFLD	1.107 (1.046-1.168)	lei	9.94e-04
Stroke	NAFLD	1.076 (0.770-1.382)		6.39e-01
		-0.5	1 2	3


Lower Risk Higher Risk





## Figure 4.





Exposure	Outcome	OR (95% CI)		P value
NAFLD	AF	1.110 (1.043-1.177)	Hel	2.36e-03
NAFLD	CAD	1.368 (1.121-1.615)	<b>⊢</b> →→	1.31e-02
NAFLD	HF	1.003 (0.883-1.123)	⊨ <b>∔</b> -I	9.67e-01
NAFLD	PAD	1.374 (1.211-1.537)	<b>⊢⊸</b> −1	1.39e-04
NAFLD	VTE	1.307 (1.099-1.515)	<b>⊢</b> •−•1	1.13e-02
NAFLD	Stroke	1.281 (-0.246-2.808)	· · · · · · · · · · · · · · · · · · ·	7.51e-01
AF	NAFLD	1.014 (0.969-1.059)		5.55e-01
CAD	NAFLD	1.102 (1.065-1.139)	101	6.30e-07
HF	NAFLD	1.128 (0.995-1.261)		7.61e-02
PAD	NAFLD	1.039 (0.965-1.113)	HeH	3.11e-01
VTE	NAFLD	1.107 (1.046-1.168)	Iel	9.94e-04
Stroke	NAFLD	1.076 (0.770-1.382)	<b>I</b>	6.39e-01
		-0.5	1 2	3
		←	Lower Risk Higher Risk	$\rightarrow$

